FDAnews
www.fdanews.com/articles/209996-genentechs-vabysmo-shows-positive-results-in-macular-edema-studies

Genentech’s Vabysmo Shows Positive Results in Macular Edema Studies

October 31, 2022

Genentech’s Vabysmo (faricimab-svoa) showed promising data in two phase 3 trials evaluating the effects of the drug on patients with macular edema due to branch and central retinal vein occlusion, which can cause loss of vision.

Participants receiving Vabysmo injections every four weeks for up to 24 weeks experienced visual acuity gains that were similar to aflibercept, a drug currently used to treat macular edema, the company said.

Vabysmo is currently FDA-approved to treat patients with neovascular/wet age-related macular degeneration and diabetic macular edema.

The drug works by neutralizing two factors that are thought to cause leaky blood vessels and increase inflammation.

View today's stories